Birch Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Birch belongs to the order Fagales and the family Betulaceae, which are widely distributed across the United States. Numerous species of birch trees can be found throughout the country, contributing to allergies. The European white birch (Betula pendula) and River birch (Betula nigra) are the two most prevalent varieties. Birch pollen is a significant allergen inhaled from the air, particularly in the northern temperate region. This pollen often leads to allergic rhinitis, asthma, and allergies to certain foods associated with pollen exposure. The prevalence of sensitivity to birch pollen is approximately 8-16% in the general population and ranges from 7-57% among patients attending various allergy clinics. The International Allergen Nomenclature Sub-committee has recognized seven allergens associated with birch pollen, with Bet v 1 being the primary allergen. To enhance diagnostic accuracy, component-resolved testing can differentiate broad cross-reactivity and prevent false-positive diagnoses of pollen allergies attributed to pan-allergens like Bet v 2, 4, or Bet v 7, from genuine birch allergies involving the main allergen Bet v 1-specific IgE. Oral Allergy Syndrome (OAS) symptoms may manifest as:
- Tingling or itching in the mouth
- Hives around the mouth
- Irritation or discomfort in the throat
- Swelling of the lips, mouth, tongue, or throat
Individuals displaying allergic reactions to birch pollen exhibit notably higher levels of serum anti-Bet v 1 IgE compared to individuals with birch sensitivity who remain asymptomatic. Elevated IgE levels related to Bet v 1 are also predictive of oral allergy syndrome following consuming fruits from the Rosaceae family, nuts, or vegetables from the Apiaceae family, which contain homologous allergens cross-reactive with birch allergens.
Thelansis’s “Birch Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Birch Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Birch Allergy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Birch Allergy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment